Maintain a healthy lifestyle and follow your specialists recommendations
doi: 10.3389/fendo.2023.1150323 212 GrandoneACapristoCCirilloGSassoMUmanoGRMarianiMet al
Tobore Kokoricha, MD , Board-Certified Internist & Functional Medicine Specialist, with 25+ years of medical expertise
Specifically, these articles warned about the hazadous downsides of pre-CHF administration of pimobendan: In "Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded, and randomized study" , published in 2007 in the Journal of Veterinary Internal Medicine, the researchers found that "PIMO has adverse cardiac functional and morphologic effects in dogs with asymptomatic MVD." In "Increased Mitral Valve Regurgitation and Myocardial Hypertrophy in Two Dogs With Long-Term Pimobendan Therapy" , published in 2005 in Cardiovascular Toxicology, the researchers concluded "This is the first report to describe an increase in mitral regurgitation under clinical conditions in dogs treated with pimobendan
BMJ Open 2025;15:e086454.ArticlePubMedPMC 116
First, it establishes the only robust human dose documented in the literature, and it comes from a strictly clinical setting with intravenous administration
